470. Longterm Clinical Outcome of HIV/HBV-Coinfected Patients Receiving Antiretroviral Therapy Including Lamivudine as the Only Agent with Anti-HBV Activity
Session: Poster Abstract Session: HIV Primary Care
Friday, October 21, 2011
Room: Poster Hall B1
Background: In patients with HIV/HBV coinfection, antiretroviral treatment (ART) regimen should include at least two anti-HBV drugs. However, in a resource-limited setting lamivudine is usually used as the only active drug for HBV in an ART regimen. We evaluated longterm clinical outcome of HIV/HBV-coinfected patients receiving ART including lamivudine as the only anti-HBV agent.

MethodsAll HBV/HIV-coinfected patients treated with ART regimen including lamivudine as the only anti-HBV drug were identified in a tertiary hospital (South Korea) from 1987 to 2008. We reviewed their clinical, laboratory, and radiological data, including CD4 cell count, liver function test, HIV/HBV viral load, liver sonography, liver disease-related event and mortality.

Results: Of 57 patients with HIV/HBV coinfection, mean age was 39±10.8 years and 93% were males. At the initiation of lamivudine therapy, median CD4 cell count was 194 cells/mm3 (range, 5-779), 48 (84%) patients had normal liver function and 4 (7%) patients had liver cirrhosis. During median follow-up period of 60 months (range, 1-126), among 48 patients with initially normal liver function, 6 (13%) patients experienced HBV reactivation, 3 (6%) patients developed liver cirrhosis and 1 (2.1%) patient died due to hepatic failure. Among 9 patients with initially abnormal liver function, 1 (11%) patient experienced HBV reactivation, 1 (11%) patient developed liver cirrhosis and 1 (11%) patient died due to hepatic failure.

Conclusion: About one fifth of HIV/HBV-coinfected patients even with initially normal liver function experienced serious liver-related events in median 5 years of ART including lamivudine as the only anti-HBV agent.

 


Subject Category: H. HIV/AIDS and other retroviruses

Gayeon Kim, MD1, Jeong-Hwan Hwang, MD1,2, Pyoeng Gyun Choe, MD1,2, Kyoung-Ho Song, MD1, Eu Suk Kim, MD, PhD1, Hong Bin Kim, MD, PhD1, Nam-Joong Kim, MD2, Wan Beom Park, MD, PhD1 and Myoung-don Oh, MD, PhD1, (1)Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, (2)Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

Disclosures:

G. Kim, None

J. H. Hwang, None

P. G. Choe, None

K. H. Song, None

E. S. Kim, None

H. B. Kim, None

N. J. Kim, None

W. B. Park, None

M. D. Oh, None

See more of: HIV Primary Care
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.